CA2592344A1 - Expression vectors for treating bacterial infections - Google Patents

Abstract

The present invention is compositions and methods for producing anti-bacterial polypeptides, and for using those compositions and methods for treating diseases and conditions caused by a bacterial infection. More specifically, the compositions and methods include treating a gram-negative bacterium with a gram-positive host that produces a polypeptide effective against the gram-negative bacterium.

Description

Expression Vectors for Treating Bacterial Infections This application is a continuation in part of U.S. Serial No. 09/883,343 60/054 (filed June 19, 2001); which is a continuation of U.S. Serial No. 08/924,629 (now U.S. Patent 6,403,082); and a continuation-in-part of U.S. Serial No.:
10/916,641 (filed August 9, 2004).

1. Field of the Invention [0001] The present invention relates to expression vectors that can be used for transferring at least one heterologous gene into, and expressing it in, a Gram-positive bacterium, preferably a lactic acid bacterium (LAB). The present invention also relates to the anti-bacterial use of the transformed host, the heterologous gene product, fermentate containing the host and/or the gene product, or combinations thereof.
II. Background of the Invention

[0002] Many bacteria produce antibacterial peptides or proteins (e.g., bacteriocins) that are generally active against other bacteria, typically closely related.
An exemplary list of bacteria and their bacteriocins are shown in Table 1.

[0003] The classical bacteriocins are the colicins produced by Escherichia coli.
Most colicins are relatively large proteinaceous compounds that are not actively secreted from the bacterial cell. Microcins produced by E. coli are peptides or polypeptides that are secreted from the cell by a dedicated export pathway and are post-translationally modified (Class I microcins) or are not posttranslationally modified (Class II microcins). Posttranslational modification requires the production of enzymes that modify the ribosomally translated peptide.

I

[0004] Bacteriocins produced by LAB are normally active against other Gram-positive bacteria, especially closely-related LABs. Likewise, bacteriocins produced by Gram-negative bacteria are against Gram-negative target strains. For example, colicin V, a bacteriocin produced by Escherichia coli, is active against a wide range of other E.
coli.

[0005] Colicin V was the first colicin discovered from E. coli. It is a Class II microcin that is synthesized as a 105 amino acid pre-peptide (leader + bacteriocin) that is cleaved to release the active 88 amino acid mature peptide. The colicin V
operon includes a structural gene, an immunity gene, and two dedicated transport genes.

[0006] A large number of LAB produce bacteriocins that include the lantibiotic peptides (Class I); non-lantibiotic peptides (Class II); and proteins (Class III). The lantibiotics, e.g., nisin produced by Lactococcus lactis subsp. lactis, are post-translationally modified and have a genetic operon consisting of about 11 genes for their synthesis, immunity, modification and export from the cell. The non-lantibiotic (Class II) bacteriocins are similar to colicin V in genetic complexity. These bacteriocins are produced as pre-peptides that are cleaved to form the mature peptide and exported from the cell in the same way as colicin V, e.g. carnobacteriocins A and B2, leucocin A, and pediocin PA-1. The non-lantibiotic divergicin A produced by Carnobacterium divergens UAL9 requires only two genes for its production and secretion from the cell.
Secretion is under the control of the cell's general secretory (sec) pathway.

Predivergicin A consists of a signal peptide and divergicin A. One gene or nucleotide sequence encodes a bacteriocin. The other gene encodes an immunity protein.

[0007] To date no bacteriocins produced by LAB have been discovered that are active against Gram-negative bacteria, such as E. coli. For reasons that will become more evident below, it may be desirable to select a Gram-positive host that produces a bacteriocin active against one or more gram-negative bacteria. For example, LAB could target E. coli if it is genetically modified (GMO) to produce a bacteriocin (such as, colicin V) or another bacteriocin that is active against another target bacterium.

[0008] Further, the ability to target a Gram-negative bacterium, such as E.
coli, using a Gram-positive bacterium that expresses a bacteriocin effective against the Gram-negative bacterium, suggests the possibility of an alternative or supplemental therapy or preventative treatment protocol against any diseases or conditions caused by the Gram-negative bacteria. An example of such a condition is post-weaning diarrhea (PWD), also known as scours, which is caused by an E. coli infection in pigs.

[0009] Outbreaks of E. coli PWD or scours are an ongoing problem in pig production. PWD or scours typically result in significant weight loss of the affected animals.

[0010] A need exists for treatments that promote weight gain or, at a minimum, result in no further weight loss during infection.

III. Summary of the Invention

[0011] The present invention provides a technology that depends on the use of LAB
that are genetically-modified (GMO) to produce heterologous polypeptides, such as bacteriocin(s), that specifically target the causative agent of a disease. One or many specific uses of the compositions and methods of the present invention include treating post weaning diarrhea (PWD) caused by enterotoxigenic Escherichia coli in weanling pigs.

[0012] This technology can be applied anywhere that Gram-positive LAB grow in a specific environment without causing harm. These environments include animal feed, such as silage; fermented foods and anaerobically- or vacuum-packaged foods, such as raw and processed meats, vegetables and pasta products; and animal (and human) gastrointestinal (GI) or urogenital tracts.

[0013] Further, some LAB strains may be probiotic (i.e., health promoting), but they may not be "targeted" against specific pathogens. In accordance with the present invention, some LAB may be targeted by genetic modification against specific pathogens, such as E. coli. Still further, the compositions and/or methods of the present invention may be preventative rather than curative. In these embodiments of the invention, the compositions and methods could be effective as a replacement for feeding sub-therapeutic levels of antibiotics as a prophylactic against GI
diseases.

[0014] The accompanying drawings show illustrative embodiments of the invention from which these and other of the objectives, novel features and advantages will be readily apparent.

IV. Brief Description of the Drawings

[0015] Figure 1 is a schematic representation of pCaT.

[0016] Figure 2 is a schematic representation of pCV22, and illustrates the replacement of the pCaT mobilization genes (mob) with a colicin V(col V) gene.

[0017] Figure 3 is a schematic representation of pCB12, and illustrates the replacement of the pCaT streptomycin resistance gene and Replb gene with a Carnobacterium immunity gene (cbiA).

[0018] Figure 4 is a schematic representation of pCB15, and illustrates the replacement in pCB12 of the cbiA gene with a brochocin C immunity gene (brcl).
pCB15 includes colicin V (illustrated), and pCB15s includes colicin VM (not illustrated).

[0019] Figure 5 provides the nucleotide and amino acid sequences of colicin V
and colicin VM. Figures 5A and 5C show the nucleotide and amino acid sequences of colicin V, respectively; and Figures 5B and 5D show the nucleotide and amino acid sequences of colicin VM, respectively.

[0020] Figure 6 is a schematic representation of pCB21, and illustrates the removal of the EcoRV restriction site from pCB 15.

[0021] Figure 7 is a schematic representation of pCB22, and illustrates the removal of the cat gene from pCB21.

[0022] Figure 8 is a schematic representation of pCB23m, and of a feed-grade vector; and illustrates the change of the colicin V gene in pCB22 to a colicin VM gene (col VM) in pCB23m.

[0023] Figure 9 is a schematic representation of pCB19, and graphically illustrates the inclusion of a polylinker containing multiple cloning sites.

[0024] Figure 10 is the nucleotide sequence of the p15 promoter.

[0025] Figure 11 is a schematic representation of the recombinant PCR
technique used to generate the DNA fragment containing the p15 promoter and colicin v gene.
The restriction sites (EcoRl and Kpnl) and the primers used are labeled.
pGKV210-p15 and pCB15 were used as templates for the first round of PCR. SP = signal peptide divergicin A; colV = colicin V gene; p15 = p15 promoter.

[0026] Figure 12 is a schematic representation of pCBIOI.

[0027] Figure 13 is a schematic representation of pCB103.

[0028] Figure 14 is a schematic representation of pCB104.

[0029] Figure 15 is a schematic representation of pCB110.

[0030] Figure 16 illustrates an expression vector pMvB of the present invention.
V. Detailed Description of the Invention

[0031] The present invention is compositions and methods for expressing a gram (-) polypeptide, such as a bacteriocin, in a Gram-positive host, such as a lactic acid bacterium. The invention also includes the use of a Gram-positive host, genetically modified according to the present invention, the polypeptide produced by the genetically modified host, compositions that include the GMO bacterium and/or the polypeptide, and combinations thereof in the treatment of susceptible bacteria.

[0032] The present invention also includes an expression vector suitable for transforming a Gram-positive host and secreting a polypeptide effective against a Gram-negative bacterium. In these embodiments of the invention, one skilled in the art will readily recognize that the expression vector may be variously configured according to the choice of host, promoter, and polypeptides used. In preferred embodiments of the present invention, the expression vectors include a signal peptide, preferably a divergicin A signal peptide, and at least one bacteriocin immunity gene. In the most preferred embodiments of the invention, the expression vector is suitable for use in a LAB host.

[0033] The present invention also includes compositions and methods for treating susceptible bacteria and the diseases or conditions caused by the susceptible bacteria.
In a preferred embodiment of the invention, some of the compositions and methods of the present invention are used to treat E. coli. In the most preferred embodiments of the invention, the compositions and methods are used to treat scours.

[0034] An embodiment of the present invention includes expression vectors for expressing a mutant colicin V bacteriocin (termed colicin VM). In this embodiment of the invention, the expression vector comprises nucleotide sequences that encode colicin VM. Exemplary nucleotide sequences include but are not limited to those shown in Seq. I.D. No. 1 and Seq. I.D. No. 3. Exemplary amino acid sequences include but are not limited to those shown in Seq. I.D. No. 2 and Seq. I.D. No. 4. One skilled in the art will recognize that various promoters signal peptides, selection markers, and other conventional elements of a functional expression vector may be used to express colicin VM.

[0035] An exemplary embodiment of the invention comprises a pCB vector comprising a P15 or P32 promoter; a divergicin A signal peptide; nucleotide sequences encoding a colicin VM; a selection marker, including but not limited to a bacteriocin immunity gene (such as brochocin-C); and a suitable replication region or regions. In the expression vector shown in Figure 4, the expression vector includes a P32 promoter, a divergicin A signal peptide, nucleotide sequences encoding colicin VM, nucleotide sequences encoding a brochocin-C immunity gene, and the replication regions ReplA and RepB from pCaT (see Jewell, et al.; Current Microbiology:
19:343-346 (1989)).

[0036] In preferred embodiments of the invention, the expression vector and the host transformed by the expression vector are food or feed-grade. In the most preferred embodiments of the invention, the host and the expression vector do not contain a gene or nucleotide sequence that encodes or confers antibiotic resistance.

[0037] Another embodiment of the present invention includes a host cell transformed by an expression vector of the present invention. In a preferred embodiment of the invention, the compositions and methods include CB4, a Lactobacillus reuteri host transformed with expression vector pCB15s that contains nucleotide sequences encoding colicin VM bacteriocin. CB4 was deposited in the American Type Culture Collection (10801 University Boulevard, Manassas, Virginia USA 20118) on 8 December 2004, and received Accession No. PTA-6426.

[0038] In these embodiments of the invention, host lactic acid bacteria are capable of expressing or secreting one or more polypeptides, including one or more bacteriocins, and include an expression vector as described herein that permit the secretion of one or more bacteriocins. The expression vector may be introduced into the host bacterium by conjugation, transformation, protoplast fusion, or other gene or nucleotide transfer method.

[0039] Another embodiment of the present invention includes an expression vector and methods of use thereof wherein the vector includes a bacteriocin immunity gene seiected from the group consisting of , but not limited to, brochocin-C and carnobacteriocin A.

SUBSTITUTE SHEET (RULE 26)

[0040] Another embodiment of the present invention includes an animal feed comprising a host bacterium transformed with an expression vector of the present invention, a bacterium produced by a transformed host of the present invention, or combinations thereof.

[0041] Another embodiment of the present invention includes a probiotic composition comprising a host bacterium transformed with an expression vector of the present invention, a bacteriocin produced by a transformed host of the present invention, or combinations thereof.

[0042] Another embodiment of the present invention includes a method of treating bacterial infections in animals or humans using a composition comprising a host bacteria transformed with an expression vector of the present invention, a bacteriocin produced by a transformed host of the present invention, or combinations thereof.

[0043] Another embodiment of the present invention includes compositions and methods for treating any E. coli susceptible to a bacteriocin expressed in accordance with the present invention. Preferred embodiments of the invention include treating E.
coli and/or the diseases and conditions caused by E. coli. The most preferred embodiments of the invention include treating post-weaning diarrhea or scours, and/or promoting weight gain or preventing weight loss, in pigs.

[0044] An expression vector of the present invention may be derived from LAB, in particular LAB of the genus Lactobacillus. The plasmids according to the invention can advantageously be stably transferred into lactic acid bacteria that belong to the genera Carnobacterium, Leuconostoc, Lactobacillus, Pediococcus, or Enterococcus, among others.

[0045] The invention also relates to a plasmid or host transformed with the plasmid, as previously defined, the plasmid comprising the nucleotide sequence SEQ ID
No. 1, or Seq. I.D. No. 3, or a sequence which differs from this sequence by the insertion, deletion or mutation of from one to several base pairs, and which retains the ability to replicate. The invention also relates to a plasmid or host transformed with the plasmid, as previously defined, the plasmid expressing the amino acid sequence comprising Seq. ID No. 2, or Seq. I.D. No. 4, or a sequence which differs from this sequence by the insertion, deletion or mutation of one to several amino acids, and which retains the ability to replicate.

[0046] The invention also relates to an expression vector as shown in Figures 2-4, 6-9, and 12-15, the vector comprising the nucleotide sequence or sequences as shown, or a sequence which differs from this sequence by the insertion, deletion or mutation of one or several base pairs and which retains the ability of the plasmid to replicate stably in suitable bacterial host cells, e.g., LAB.

[0047] The invention also relates to bacterial host cells that comprise an expression vector according to the invention. Exemplary expression vectors of the present invention include but are not limited to pJKM37, pCV22, pCB12, pCB15, pCB15s, pCB21, pCB22, pCB23M, pCB19, pGKV210, pGKV210-P15, pCB101, pCB103, pCB104, pCBIIO, and pCBIII. Exemplary hosts transformed by at least one of these expression vectors include but are not limited to Carnobacterium maltaromaticum UAL26, Lactobacillus reuteri CB4, two other strains of Lactobacillus reuteri and one strain of Lactobacillus johnsonii.

[0048] Because of the breadth of host cells that can be used for transformation purposes, the plasmids according to the present invention constitute outstanding tools for cloning and expressing heterologous nucleotide sequences in host LAB.

[0049] In particular, the plasmids according to the invention can be used for expressing heterologous proteins, such as bacteriocins, and proteins for resistance to these bacteriocins, also termed immunity proteins.

[0050] Each of these elements will now be described in more detail.

[0051] In accordance with the present invention, any suitable host bacterium may be used. In preferred embodiments of the invention, the host bacterium is a Gram-positive bacterium. In the most preferred embodiments of the invention, the host bacterium is a lactic acid bacterium (LAB). Exemplary suitable host include, but are not limited to, those shown in Table 1 and in the Examples. The choice of a suitable host is well within the skill of one skilled in the art.

[0052] In preferred embodiments of the invention, the host is L. reuteri. In the most preferred embodiments of the invention, the host is CB4, a Lactobacillus reuteri strain.

[0053] In accordance with the present invention, any promoter suitable for use with expressing a bacteriocin gene may be used. For example, any promoter may be employed that is compatible with the host strain in which the secretion system of the present invention is used. Suitable promoters and the choice of a particular promoter are apparent to one skilled in the art. Suitable exemplary promoters include but are not limited to P15 and P32. See for example U.S. Patent 5,939,317, incorporated herein by reference. In preferred embodiments of the invention, the expression vector includes a P15 promoter, operatively associated with the bacteriocin gene of interest. In accordance with the present invention, a promoter having nucleotide sequences corresponding to Seq. ID No. 5 may be used (see Figure 10).

[0054] In accordance with the present invention, any signal peptide suitable for use with expressing a bacteriocin gene may be used. Suitable signal peptides include, but are not limited to, a signal peptide of divergicin A. In preferred embodiments of the invention, the expression vector includes a divergicin A signal peptide, operatively associated with the bacteriocin gene of interest. In accordance with the present invention, a divergicin A signal peptide having nucleotide sequences corresponding to those disclosed in U.S. Patent 6,403,082 (Stiles et al.), incorporated herein by reference, may be used.

[0055] In accordance with the present invention, any bacteriocin gene may be used.
See, for example, Table 1. Suitable bacteriocin genes include but are not limited to colicin V, colicin Y101, colicin VM, leucocin A, and brochocin-C. In preferred embodiments of the invention, the expression vector includes a nucleotide sequence or gene encoding one of more of the above bacteriocins. In the most preferred embodiments of the invention, the expression vector comprises nucleotide sequences or a gene encoding colicin VM. Exemplary nucleotide sequences for a bacteriocin are well known to those skilled in the art. See, for example, U.S. Patent 6,403,082 (Stiles, et al.).

[0056] In accordance with the present invention, the compositions and methods include a host and/or an expression vector that comprises nucleotide sequences or a gene that encodes a mutated colicin V that contains the following nucleotide sequence:
gtggctggaggtgtggctggaggt (Seq. I.D. No. 1). See Figure 5B. In a most preferred embodiment of the invention, the compositions and methods include a host and/or an expression vector that comprises nucleotide sequences or a gene that encodes a mutated colicin V that contains the nucleotide sequences shown in Figure 5B
(Seq., I.D.
No. 3).

[0057] In accordance with the present invention, the compositions and methods include a host and/or an expression vector that encodes the following colicin VM amino acid sequence: VAGGVAGG (Seq. I.D. No. 2). In a most preferred embodiment of the invention, the compositions and methods include a host and/or an expression vector that encodes A colicin VM amino acid sequence corresponding to (Seq. I.D. No.
4).
See Figure 5D.

[0058] In accordance with the present invention, any selection marker suitable for use with expressing a bacteriocin gene may be used. Suitable selection markers include but are not limited to immunity genes for carnobacteriocin A, piscicolin 126, and brochocin-C; and antibiotic resistance genes, e.g., chloramphenicol, erythromycin, and streptomycin. In preferred embodiments of the invention, the expression vector includes a bacteriocin immunity gene, preferably a brochocin C immunity gene, operatively associated with the bacteriocin gene of interest. Exemplary nucleotide sequences for an immunity gene are well known to those skilled in the art.
See, for example, U.S. Patent 6,403,082 (Stiles, et al.), incorporated herein by reference. As noted above, it may be highly desirable to produce and use a feed-grade vector and host; such vectors and host lack functional antibiotic resistance genes and, in accordance with the present invention, include nucleotide sequences or genes that encode bacteriocin immunity.

[0059] The invention also includes a method of treating a bacterial infection or a method of treating an animal (including a human) by administering or contacting the bacteria or animal with one or more of the following compositions: a composition comprising one or more hosts transformed by an expression vector of the present invention; a composition comprising one or more bacteriocins produced by a transformed host; one or more bacteriocins produced naturally or by GMO (see, for example Table 1); or combinations thereof.

[0060] In preferred embodiments of the invention, any of the compositions of the present invention may be used to treat an E. coli disease or condition, including but not limited to scours. In some embodiments of the invention, any of the compositions of the present invention may be used to promote weight gain in the subject animal. In some embodiments of the present invention, any of the compositions of the present invention may be used to treat or affect indigenous microflora in the treated subject.

[0061] An embodiment of the present invention includes expression vector pMvB, comprising a suitable promoter, e.g., P15; a signal peptide encoding DNA, e.g., divergicin A signal peptide; a gene encoding a polypeptide, e.g., encoding a bacteriocin, including but not limited to colicin V; a selection marker, including but not limited to a bacteriocin immunity gene, e.g., brochocin C; and a suitable replication region or regions, e.g., pCaT (a commercially available plasmid).

[0062] In preferred embodiments of the invention, sequences from a pCaT
plasmid that is not required and/or unwanted (such as antibiotic markers and mobilization genes) are deleted to result in a fragment of pCaT that may be used as a replicon. In accordance with the present invention, several additions are made to the pCaT
replicon, including but not limited to any desired genes (such as bacteriocin and immunity genes), promoters (such as P15) and expression signals. In accordance with the present invention, a replication sequence (or replication sequences) suitable for use in a lactic acid bacteria host may be used. Suitable replication sequences include but are not limited to the replication region(s) of pCaT. In preferred embodiments of the invention, the replication sequences include a pCaT segment derived from L.
plantarum.
Definitions

[0063] The term "gene" as used herein refers to a DNA sequence, including but not limited to a DNA sequence that can be transcribed into mRNA which can be translated into polypeptide chains, transcribed into rRNA or tRNA or serve as recognition sites for enzymes and other proteins involved in DNA replication, transcription and regulation.
These genes include, but are not limited to, structural genes, immunity genes and secretory (transport) genes.

[0064] The term "vector" as used herein refers to any DNA material capable of transferring genetic material into a bacterial host organism. The vector may be linear or circular in topology and includes but is not limited to plasmids, food grade plasmids or bacteriophages. The vector may include amplification genes, enhancers or selection markers and may or may not be integrated into the genome of the host organism.
The term "secretion vector" or "expression vector" refers to a vector designed to provide secretion of a polypeptide such as a protein from the host organism.

[0065] The term "signal peptide" as used herein refers to amino-terminal amino acid residues that, when attached to a target polypeptide, permits the export of the target {E4258651. DOC;1 } 15 polypeptide from the cell and cieavage of the signal peptide. The signal peptide accesses the general protein secretion pathway. An example of a signal peptide is the Divergicin A signal peptide described in U.S. Patent 6,403,082, incorporated herein by reference. Other signal peptides can be used and are known to those skilled in the art.

[0066] The term "feed or food-grade" as used herein refer to the origin of the DNA
material and its constituents. Food-grade indicates that a regulatory agency would consider the substance as coming from a food source and therefore suitable for inclusion in food or food products, typically those intended for human or animal consumption. Organisms that are food-grade, such as lactic acid bacteria and other established genera of starter organisms, can be added directly to food without concern for pathogenicity. Food or feed grade as used herein aiso refers to the quality of a substance, specifically whether it is free of elements or the like that might be undesirable. A food or feed grade expression vector or a food or feed grade bacterium of the present invention is free of or lacks an antibiotic resistance gene, or is free of or lacks an expressible or functional antibiotic resistance gene. In preferred embodiments, the food or feed grade compositions of the present invention may be used in or comprise silage, foods, feeds, diary products, meat, vegetables, or pasta.

[0067] The term a "bacteriocin" as used herein refers to polypeptides and the like produced by the bacteria that inhibit one or more bacterial species. This includes, but is not limited to, polypeptides that are derived from specific strains of bacteria, proteins that are derived from other types of organisms, or proteins developed through genetic engineering. The bacteriocin can be bacteriostatic or bactericidal.

[0068] The term "immunity gene" as used herein refers to a gene that produces a protein that protects the host organism against the bacteriocin that it produces. An immunity gene may also be used as a selection marker.

[0069] The term "susceptible bacterium" as used herein refers to a species or strain of bacteria that is inhibited by the presence of one or more bacteriocins in its environment.

[0070] Although the present invention has been described in terms of particular preferred embodiments, it is not limited to those embodiments. Alternative embodiments, examples, and modifications that would still be encompassed by the invention may be made by those skilled in the art, particularly in light of the foregoing teachings.

Table 1 Strain Bacteriocin Our lab collection of LAB
1. Carnobacterium maltaromaticum CB1 carnobacteriocin BM1, piscicolin 126 +
unknown 2. C. maltaromaticum CB2 carnobacteriocin BM1, piscicolin 126 + unknown 3. C. maltaromaticum CB3 carnobacteriocin BM1, piscicolin 126 4. C. maltaromaticum UAL26 piscicolin 126 5. C. maltaromaticum LV17 carnobacteriocin A, BMI and B2 6. C. maltaromaticum UAL26/8A piscicolin 126, carnobacteriocin A
7. Carnobacterium divergens LV13 divergicin A
8. Leuconostoc gelidum UAL187 leucocin A
9. Lactobacillus sakei UAL185 unknown 10. Leuconostoc spp. UAL280 unknown Non-LAB inhibiting Listeria spp.
11. Brochothrix campestris ATCC43754 brochocin C
12. Staphylococcus aureus A53 aureocin A53 13. Brevibacterium linens ATCC9175 unknown 14. B. linens OC2 linenscin OC2 15. Bifidobacterium bifidumNCFB1454 bifidocin B
Meat applied LAB inhibiting Listeria 16. C. maltaromaticum LV61 carnobacteriocin A
17. C. maltaromaticum V1 carnobacteriocin BM1, piscicolin 126 18. C. maltaromaticum CP5 carnobacteriocin BM1 and B2 19. C. maltaromaticum JG126 piscicolin 126 20. Carnobacterium spp. 377 carnocin H
21. C. maltaromaticum U149 carnocin U149 22. C. divergens 750 divergicin 750 23. Pediococcus acidilactici PAC1.0 pediocin PA-1 24. P. acidilactici E pediocin PA-1 25. P. acidilactici F pediocin PA-1 26. P. acidilactici H pediocin PA-1 27. P. acidilactici JD1-23 pediocin PA-1 28. P. acidilactici M pediocin PA-1 29. P. pentosaceous Z102 pediocin PA-1 30. Lactobacillus plantarum WHE92 pediocin PA-1 31. L. plantarum ALC01 pediocin PA-1 32. Lactobacillus sakei Lb706 sakacin A
33. Lb. sakei CTC494 sakacin A
34. Lactobacillus curvatus LTH1174 sakacin A
35. Lb. sakei LTH673 sakacin P
36. Lb. sakei 674 sakacin P
37. Lactobacillus bavaricus MI401 sakacin P
38. Lb. sakei MN bavaricin MN
39. Enterococcus faecium CTC492 enterocin A and B

40. E. faecium T136 enterocin A and B
41. E. faecium WHE81 enterocin A and B
42. E. faecium BFE900 enterocin A and B
43. E. faecium L50 enterocin L50A and L50B, P, Q
44. E. faecium DPC1146 enterocin A
45. E. faecium EK13 enterocin A and P
46. E. faecium P13 enterocin P
47. E. faecium AA13 enterocin P
48. E. faecium G16 enterocin P
49. E. faecium JCM5804T enterocin A, B, P
50. Enterococcus casseliflavusIM416K1 enterocin 416K1 51. Leuconostoc carnosum 4010 leucocin A and C
52. Lb. plantarum UG1 plantaricin UG1 53. E. faecium CRL35 enterocin CRL35 54. Lactobacillus casei CRL705 lactocin CRL705 55. Lb. sakei CTC494 sakacin K
56. L. carnosum leucocin F10 57. L. carnosum leucocin B-Ta 11 a 58. Lactobacillus brevis VB286 brevicin 286 59. Lb. plantarum CTC305 unknown 60. Lb. plantarum CTC306 unknown 61. Lb. sakei CTC372 unknown LAB inhibiting Listeria 62. C. maltaromaticum CS526 unknown 63. Streptococcus thermophilus Sfi13 thermophilin 13 64. E. faecalis EJ97 enterocin EJ97 65. E. faecalis BFE1071 enterocin 1071 66. E. faecalis FAIR-E309 enterocin 1071 67. E. faecalis Y1717 bacteriocin 31 68. E. faecalis LMG2333 enterolysin A
69. E. faecalis DPC5280 enterolysin A
70. E. faecalis S-48 enterocin AS-48

71. E. faecalis INIA4 enterocin AS-48

72. Lb. plantarum ALC 1 pediocin PA-1

73. Lb. sake 2512 sakacin G

74. Lb. plantarum 423 plantaricin 423

75. Enterococcus mundtii ATO6 mundticin

76. E. mundtii NFR17393 mundticin KS

77. Lactobacillus buchneri buchnericin-LB

78. L. lactis MMFII lactococcin MMFII

79. L. /actis UL720 diacetin B

80. Enterococcus gallinarum 012 enterocin 012

81. Lb. plantarum plantaricin NA

82. Leuconostoc mesenteroides FR52 mesenterocin 52A

83. L. mesenteroides Y105 mesentericinY105 Lantibiotics inhibiting Listeria

84. L. lactis nisin

85. L. lactis nisin Z

86. L. lactis 61-14 nisin Q

87. L. lactis DPC3147 lacticin3147 Other bacteriocin producing bacteria

88. L. lactis lactococcin A, B, M

89. L. lactis LMG280 lactococcin G

90. L. /actis IPLA972 lactococcin 972

91. L. lactis DPC5552 lacticin 481

92. L.lactis BGMN1-5 LsbA, LsbB

93. Lactobacillus johnsonirVPI11088 lactacin F

94. Lactobacillus acidophilus M46 acidocin B

95. Lb. acidophilus N2 lactacin B

96. Lactobacillus gasseri LA39 gassericin A

97. Lactobacillus salivarius UCC118 ABP-1 18

98. L. plantarum C11 plantaricn E/F, J/K

99. L. plantarum NC8 plantaricin NC8

100. Propionibacterium jensenii DF1 propionicin SM1

101. Escherichia coli colicin V

102. E. coli colicin Y101

103. E. coli microcin H47

104. Staphylococcus epidermis epidermin

105. Bacillus subtilis 168 subtilosin A

106. Lb. gasseri gassericin K7B

107. Klebsiella pneumoniae microcin E492

108. Clostridium tyrobutyricumADRIAT932 closticin574

109. Clostridium beyerinc{cii ATCC25752 circularin A

110. Lactobacillus amylovorus DCE471 amylovorin L471

111. Lb. plantarum SA6 plantaricin SA6

112. Lb. salcei L45 lactocinS

The following bacteriocins are called microcins produced by gram-negative bacteria:
1. Klebsiella pneumoniae RYC492 microcin E492 (same as 107) 2. E. coli microcin V (same as 101, colicin is "old" name) 3. E. coli microcin Y101 (same as 102) 4. E. coli microcin H47 5. E. coli microcin L
6. E. coli microcin 24 Examples The following examples are provided as a guide for those skilled in the art to carry out the invention.

GENERAL MATERIALS AND METHODS

Escherichia coli DH5a cells were grown in Luria Broth (LB) medium (Difco Laboratories Inc.) at 37 C; Carnobacterium maltaromaticum UAL26 was grown in APT
(All Purpose Tween) medium (Difco) at 25 C; and Lactobacillus reuteri CB4 was grown in Lactobacilli MRS medium (MRS; Difco) at 37 C. Bacteriocin production was tested as described previously (van Belkum and Stiles, 1995). Colicin V production was tested using E. coli (DH5a) as the indicator organism grown on APT medium supplemented with 1.5% (wt/vol) agar for solid plating. Selective concentrations of chloramphenicol for growth of UAL26 and CB4 containing recombinant plasmids were 5 and 10 pg/mI, respectively. Cloning and DNA manipulations were performed as described by Sambrook et al. (1989). Enzymes used for molecular cloning were obtained from Invitrogen and used as specified by the manufacturer. Plasmid isolation was done as described by van Belkum and Stiles (1995). Nucleotide sequencing was based on the method of Sanger et al. (1977) and done in a Perkin-ElmerABl-Prism DNA
sequencer with fluorescent chain terminators. For transformation of UAL26 and CB4, cells were grown in APT or MRS medium supplemented with 2% (wt/vol) glycine, respectively.
Exponentially growing cells were harvested and washed twice with ice-cold water and twice with ice-cold electroporation buffer (0.5 M sucrose, 10% glycerol, 1 mM
MgC12, 5 mM potassium phosphate buffer [pH6] and concentrated 100-fold in the same buffer.
Cells were divided into 50 lal portions and stored at -70 C. Electroporation was done as described by van Belkum and Stiles (1995) with the following modification for CB4: cells were incubated at 44 C for 20 min and chilled on ice for an additional 10 min prior to the addition of DNA. Electroporation was done in a Gene-Pulser instrument (Bio-Rad). One pulse of 25 pF, 200 0, 2.5 kV was used for UAL26 and one pulse of 25 pF, 800 0, 1.0 kV for CB4.

Example I
Use of plasmid pCaT and its derivatives as cloning vectors in LAB

Figure 1 shows a schematic representation of plasmid pCaT from Lactobacillus plantarum caTC2R (Jewell and Collins-Thompson, 1989). The pCaT plasmid was reported to contain the genetic information for chloramphenicol resistance (cat gene).
The inventors have fully sequenced and partially characterized the plasmid.
The plasmid has been transformed into various Carnobacterium spp., L. plantarum NC8 and L. caseiATCC 393, demonstrating chloramphenicol resistance in these strains (Ahn et al., 1992). The pCaT plasmid contains 8951 base pairs. Several putative genes were located, including genes involved in replication (repB, repla and replb), mobilization (mob), antibiotic resistance for chloramphenicol (cat) and streptomycin (str), and a truncated open reading frame that could encode a transposase (Tase) (See Figure 1).
The inventors have used pCaT as a cloning vector for genes related to the production of proteins such as, but not limited to, bacteriocins produced by Gram-positive bacteria.
The P32 promoter was isolated from Lactococcus lactis subsp. lactis (van der Vossen et al., 1987) and this promoter been used to express colicin V gene in pJKM37 (McCormick et al., 1999). Plasmid pJKM37 contains P32 promoter, divergicin A
signal peptide, and colicin V gene (coN). A 28-mer oligonucleotide, (5' - CCC GCA TGC
TGA
ATT CGG TCC TCG GGA T - 3') (Seq. I.D. No. 6) containing a Sphl restriction site (underlined) that is added to a sequence homologous to the 5' end of the nucleotide sequence containing the P32 promoter in pJKM37 and a 28-mer oligonucleotide, (5' -CCC GCA TGC GGT ACC ACT ATT TAT AAA C- 3') (Seq. I.D. No. 7) containing a Sphi restriction site (underlined) that is added to a sequence homologous to the 3' end of the nucleotide sequence containing the structural gene for colicin V in pJKM37 were used for the PCR reaction with pJKM37 as a template. The PCR product containing P32 promoter and colicin V gene (coN) fused to divergicin A signal peptide was digested with Sphl. The digested PCR product was cloned into pCaT by replacing the 2.1 kb Sphl fragment of pCaT containing the mobilization genes. The resulting plasmid, pCV22 (Figure 2), was transformed into a plasmidless host, Carnobacterium maltaromaticum UAL26. These transformed cells inhibited the growth of the colicin V
sensitive indicator strain E. coli DH5a.
Example 2 Introduction of bacteriocin immunity genes as selection markers into colicin V
producing pCaT derivatives transformed into LAB
Immunity genes for bacteriocins were introduced into pCV22 as genetic selection markers. Two different functional polynucleotide sequences encoding bacteriocin immunity proteins were selected for this procedure: carnobacteriocin A
immunity gene and brochocin-C immunity gene (Franz et al., 2000; McCormick et al., 1998). In plasmid pCF08 the mid-sequence encoding carnobacteriocin A immunity was cloned behind the P32 promoter (functional) (Franz et al., 2000). A 28-mer oligonucleotide (5'-TAT ATG
ATC AGG TCC TCG GGA TAT GAT A- 3') (Seq. I.D. No. 8) containing a Bcll restriction site (underlined) was added to a sequence homologous to the 5' end of the nucleotide sequence containing the P32 promoter in pCF08 (Franz et al., 2000) and a 28-mer oligonucleotide (5' - TAT ACT GCA GGG TAC CGT CTA CAG TCT G - 3') (Seq. I.D.
No. 9) containing a Pstl restriction site (underlined) was added to the 3' end of the nucleotide sequence encoding carnobacteriocin A immunity protein in pCF08 were used to amplify the sequence encoding carnobacteriocin A immunity gene under the control of P32. This PCR product was cloned into pCV22 using Bc1I and Psti restriction sites.
The carnobacteriocin A immunity gene of the resulting plasmid, pCB12 (Figure 3), was subsequently replaced by the immunity gene for the bacteriocin brochocin-C. A
40-mer oligonucleotide (5' - ATA TAT CGA TAG GAA GTA TGA TCAATG GTAAAAACT ATA C
- 3') (Seq. I.D. No. 10) containing a Clal restriction site (underlined) was added to the 5' end of the brochocin-C immunity gene in pJKM61 (McCormick et al., 1998) and a mer oligonucleotide (5' - ATA TCT GCA GAT ATC TAG TTA GAG AAT ATA ATC CA - 3') (Seq. I.D. No. 11) containing a Pstl restriction site (underlined) was added to the 3' end of the brochocin-C immunity gene in pJKM61 were used to amplify the immunity gene for brochocin-C. This PCR product was cloned into the Clal and Pstl restriction sites of pCB12, resulting in plasmid pCB15 (Figure 4). Plasmid pCB15 was transformed into C.
maltaromaticum UAL26. The transformed strain inhibited the growth of colicin V
sensitive indicator organism such as E. coli DH5a and showed immunity to brochocin-C

[20% heat-treated (100 C for 5 min) spent supernatant from a culture of Brochothrix campestris ATCC 43754 in APT medium].

Example 3 Isolation and selection of Lactobacillus reuteri CB4 for use as a host to develop a targeted probiotic organism The gastrointestinal tract (GIT) of two healthy pigs was obtained from a small, provincially inspected meat packing plant at time of slaughter. The GIT was excised, sealed at the anterior and posterior ends and transported to the Animal Science laboratory at the University of Alberta Research Station (Edmonton, Canada).
The GIT
was flushed with tap water to remove the intestinal contents and segments were excised from the pars esophagea, ileum, jejunum, cecum and colon. The internal surface of the excised segments was scraped with a sterile microscope slide to remove the surface of the epithelial layer.
The scrapings were washed into a dilution bottle, plated onto Difco Lactobacilli MRS agar (MRS) and incubated anaerobically at 37 C for 18 to 24 hours. A total of 18 morphologically distinct colonies was randomly selected and checked for Gram-positive, catalase negative, rod-shaped characteristics and inoculated into MRS broth for storage. These strains were checked for bacteriological purity and tested for transformability with pCB15. Only Lactobacillus spp. that could be transformed were selected for further study. The isolate CB4 was able to be transformed, and was confirmed to be Lactobacillus reuteri by 16S rDNA analysis (Willson et al., 1990). L.
reuteri CB4 was chosen as a strain of interest based on the stability of the transformed plasmid.

Example 4 Production of a mutated colicin V bacteriocin, colicin VM, in Lactobacillus reuteri CB4 Electroporation of pCB15 isolated from C. maltaromaticum UAL26 into L. reuteri CB4 resulted in a low transformation rate. A L. reuteri CB4 transformant was isolated that contained a plasmid denoted pCB15s, that was stable in the host strain and produced a bacteriocin that inhibited growth of colicin V-sensitive indicator organisms such as E. coli DH5a. The plasmid pCB15s from L. reuteri CB4 was isolated from this transformant and electroporated back into plasmidless C. maltaromaticum UAL26.
When pCB15s that was re-isolated from these C. maltaromaticum UAL26 transformants was electroporated back into L. reuteri CB4 a significantly higher transformation frequency was obtained. Nucleotide sequencing of the inserted colicin gene revealed the presence of a mutation in the colicin V gene consisting of a duplication of the nucleotide sequence 5' GTGGCTGGAGGT 3' (Seq. I.D. No. 12). This resulted in duplication of amino acids 29 to 32 of colicin V to give Val-Ala-Gly-Gly-Val-Ala-Gly-Gly (Seq. I.D. No. 13). Hence, the mutated colicin V was named colicin VM. The colicin VM
consists of 92 amino acids instead of the 88 amino acids that constitute colicin V (Figure 5). Both C. maltaromaticum UAL26 and L. reuteri CB4 transformants containing pCB15s inhibited E. coli DH5a indicating that colicin VM retains antibacterial activity against E.
coli.

Example 5 Use of genetically modified bacteria producing recombinant colicin VM as a preventative treatment for Post Weaning Diarrhea (PWD) of pigs The host strains for use in this technology will be harmless or beneficial (probiotic) microorganisms that are commonly associated with the GI tract of the target animal. Post-weaning diarrhea (PWD) that causes morbidity or mortality of pigs.is an example of a GI disease that can be prevented using this technology.
The efficacy of the transformed host strain, Lactobacillus reuteri CB4 containing pCB15s, producing colicin VM (colVM) to target enterotoxigenic Escherichia coli (ETEC) that cause post-weaning diarrhea (PWD) in pigs was determined. The organism was tested in an established pig infection model. Efficacy of the preventative treatment is measured by reduction of PWD and normal weight gain of the weanling pigs.
Twenty 17-day-old weaned piglets were divided into two groups of 10 pigs.
Group 1 was untreated and Group 2 was treated by administration of approximately I x 109 L. reuteri CB4, containing pCB15s in the drinking water from Day 1 to Day 9 of the experiment. On Day 7 both groups were challenged with approximately 5 x 108 of an ETEC-F4 strain (known to cause PWD), administered by oesophageal tube. In the model the presence of F4 receptor-positive animals (those specifically susceptible to colonization by the ETEC-F4 strain) were selected for separate analysis.
Health of the experimental animals was monitored and on Day 10 they pigs were euthanized for necropsy.
The effect of the test organism was measured by analysis of weight gain, the diarrhea score, consistency of the intestinal contents and colonization of the ileum by the challenge strain at the day of necropsy.

Results:
From the day of the challenge to the day of necropsy the daily weight gain of Group 2 was higher (continued to grow) than Group 1(did not grow).
In Group 2, the administration of the L. reuteri CB4 containing pCB15s, resulted in improved intestinal consistency, particularly in the jejunum and the ileum, and reduced diarrhea scores.
In Group 2 colonization of the ileum with the ETEC-F4 challenge strain was decreased by 1 log compared with Group 1.
The benefit of feeding L. reuteri CB4 containing pCB15s to weaned pigiets was demonstrated by continued weight gain after the challenge and reduced incidence and degree of diarrhea. In various trials, a significant number of piglets gained weight after the E. coli challenge, as compared to control piglets; and a significant number of piglets exhibited reduced and degree of diarrhea in response to the E. coli challenge, as compared to the control piglets.
These data were confirmed by results of additional challenge studies.
Example 6 Production of a mutated colicin V bacteriocin, colicin VM, in a feed-grade vector In these examples a feed-grade vector is a plasmid that lacks or contains a truncated antibiotic resistance genes and uses an alternate selection system, such as a bacteriocin immunity gene, for animal feed applications.

To inactivate the cat gene, a derivative of pCB15, named pCB21 (Figure 6), was made that has unique EcoRV and BstEll restriction sites in the cat gene. To ensure that the cat gene EcoRV site was unique, an EcoRV restriction site located immediately downstream of the brochocin-C immunity gene of pCB15 was removed by the following procedure: a 40-mer oligonucleotide (5' - ATA TAT CGATAG GAA GTA TGA TCAATG
GTA AAA ACT ATA C - 3') (Seq. I. D. No. 14) described in Example 2, and a 27-mer oligonucleotide (5' - ATA TCT GCA GTC TAG TTA GAG AAT ATA - 3') (Seq. I. D.
No. 15) containing a Pstl restriction site (underlined) fused to the homologous 3' end of the brochocin-C immunity gene in pJKM61 were used to amplify the immunity gene for brochocin-C. This PCR product was cloned into the Clal and Pstl restriction sites of pCB15 to replace the brochocin-C immunity gene that contained the downstream EcoRV restriction enzyme site and transformed into C. maltaromaticum UAL26.
The resulting plasmid, pCB21 (See Figure 6), obtained from the transformants was digested by EcoRV and BstEll, filled in by DNA polymerase I and dNTPs, self-ligated, and transformed into C. maltaromaticum UAL26. UAL26 transformants were selected by plating on APT plates containing 20% heat-treated (100 C for 5 min) spent supernatant from a culture of Brochothrix campestris ATCC 43754 grown in APT medium. The resulting UAL26 transformants contained plasmid pCB22 (Figure 7) and were sensitive to chloramphenicol and produced colicin V.
To achieve the production of colicin VM using a feed-grade vector in strains of lactobacilli that are unable to produce the native colicin V, the following cloning experiment was done. The 1.5-kb EcoRl-Pstl fragment from plasmid pCB15s containing the colicin VM gene was isolated and cloned into the EcoRI-Pstl restriction sites of plasmid pCB22. The resulting plasmid, pCB23M (Figure 8), lost the 1.5-kb EcoRl-Pstl fragment that contains the native colicin V gene because it was replaced by the 1.5-kb EcoRl-Pstl fragment that contains the colicin VM structural gene.
C.
maltaromaticum UAL26 containing pCB23M inhibited E. coli DH5a, was immune to brochocin-C and sensitive to chloramphenicol. Plasmid pCB23M was isolated from C.
maltaromaticum UAL26 and transferred by electroporation into L. reuteri CB4 using 4000 AU/mI of brochocin-C as selection agent. Transformants of CB4 containing pCB23M were sensitive to chloramphenicol, immune to brochocin-C and inhibited growth of the indicator organism E. coli DH5a. This result showed that we obtained a strain of L. reuteri CB4 that inhibited E. coli using a feed-grade plasmid.

Example 7 Use of plasmid pCB19 as a cloning vector in LAB
A cloning vector pCB 19 based on pCaT was constructed by introducing a multiple cloning site that can be used to clone DNA fragments of interest. A
4.6-kb Sphl-Pstl DNA fragment from pCaT that contains the open reading frames that could encode proteins involved in horizontal transfer of plasmids as well as the streptomycin resistance gene was replaced by a polylinker (5'-GCA TGC GAA TTC GAG CTC GGT
ACC CGG GGA TCC TCC TGC AG-3') (Seq. I.D. No. 16) that contains multiple cloning sites (Figure 9). The resulting 4.3-kb plasmid, pCB19 (See Figure 8), can be selected when transformed into lactic acid bacteria using the chloramphenicol resistance gene (cat). This plasmid has been transformed into lactic acid bacteria such as C.
maltaromaticum and L. reuteri. Other selection markers including, but not limited to, bacteriocin immunity genes can be cloned into the multiple cloning sites of pCB19. The inventors have demonstrated that genes encoding proteins such as bacteriocins can be cloned into the multiple cloning sites of pCB19 resulting in export of the recombinant proteins by the lactic acid bacteria.

Example 8 Screening promoter from C. maltoromaticum strain To investigate whether other suitable promoters can be found to express bacteriocin production in LAB, a promoter from the chromosomal DNA of C.
maltaromaticum LV17 was cloned. Chromosomal DNA was isolated by the inventors from C. maltaromaticum LV17, digested completely with the restriction enzyme Mbol and cloned into the promoter screening vector pGKV210 (van der Vossen et al., 1985).
The ligation mixture was transferred by electroporation into C. maltaromaticum and transformants were selected on APT agar plates containing 20 pg of chloramphenicol per ml. One such transformant obtained, designated as pGKV210-P15, grew on APT plates with chloramphenicol concentration as high as 45 to 50 pg/ml. The promoter in pGKV210 that was isolated from C. maltaromaticum LV17 was labeled P15.
A pair of primers, MP11 forward primer 5' GAATTCGAGCTCGCCCGG 3' (Seq.
I.D. No. 17) containing a EcoRl restriction site (underlined) and reverse primer 5' CTGCAGGTCGACTCTAGAG 3' (Seq. I.D. No. 18), were used to amplify the insert containing the P15 promoter from pGKV210-P15. The sequence of the fragment containing the P15 promoter was determined and showed to contain 276 nucleotides (Figure 10).
Recombinant PCR technique was used to construct plasmids expressing the colicin V gene using the P15 promoter (Figure 11). The MP11 forward primer (5' GAATTCGAGCTCGCCCGG 3') (Seq. I.D. No. 19) and a reverse primer A(5' TGTGATACCAAGATGCATTCAACCATATTTGAAG 3') (Seq. I.D. No. 20), which is complemented to the 3' - end of P15 promoter and the DNA encoding the N-terminus of leading peptide of divergicin A, were used to amplify the P15 promoter fragment.
Primers B(5' TATGGTTGAATGCATCTTGGTATCACAAACTAA 3') (Seq. I.D. No. 21) and C(5' CCCGGTACCACTATTTATAAACAAACATCAC 3') (Seq. I.D. No. 22) (McCormick et al., 1999) were used to amplify the DNA encoding colicin V and the signal peptide of divergicin A using plasmid pCB15 DNA as the template. Primer B is complementary to the 3' end of the P15 promoter fragment and the DNA encoding the N
terminus of the signal peptide of divergicin A. Primer C contains a Kpnl restriction site (underlined) and is used as the reverse primer for co1V. Subsequently, the two PCR
products from above were used as templates and the primers MP11 forward and C
were used for recombinant PCR to amplify the fragment containing the DNA from both PCR products. The resulting PCR product contains P15 promoter, in front of DNA
encoding colicin V fused to the signal peptide of divergicin A.
The above PCR fragment was digested with EcoRl and Kpnl restriction enzymes and inserted into the appropriate sites of pCB19, giving plasmid pCB101 (Figure 12).
Plasmid pCB101 was transferred by electroporation into C. maltaromaticum UAL26.
The strain containing pCB101 inhibited the growth of colicin V indicator strain E. coli DH5a.

Example 9 Production of colicin V using P15 promoter in C. maltaromaticum using a feed-grade vector Primer (5' GTAACTCTAGAAGGAAGTATGATCAATGGTA 3') (Seq. I.D. No. 23) containing a Xbal site (underiined) and primer (5' TATCTGCAGTCTAGTTAGAGAATAT
AATCCA 3') (Seq. I.D. No. 24) containing a Pstl site (underlined) were used to amplify the brochocin-C immunity gene using pCB15 DNA as the template. The PCR product was inserted into the appropriate sites of pCB101, giving the plasmid pCB103 (Figure 13). When pCB103 was transformed into C. maltaromaticum UAL26, the strain containing the plasmid inhibited the growth of E. coli DH5uc and was resistant to chloramphenicol.
To construct a feed-grade vector containing coIV, plasmid pCB103 was digested with the unique restriction enzyme sites EcoRV and BstEll, which are located within the cat gene, to remove most of the cat gene. The linear fragment was blunted by DNA
polymerase I, self-ligated and transformed into C. maltaromaticum UAL26. The resulting feed-grade plasmid pCB104 contains the DNA encoding the signal peptide of divergicin A, fused to colicin V, and brochocin-C immunity, under control of the P15 promoter (Figure 14). C. maltaromaticum UAL26 containing pCB104 was selected on APT
agar plates containing 80 AU of brochocin-C per ml. The activity units of brochocin-C using Carnobacterium divergens LV13 (Worobo et al. 1995) as the indicator organism were determined as described previously (van Belkum and Stiles, 1995). These strains inhibited the growth of E. coli DH5a, and were sensitive to chloramphenicol.
C. maltaromaticum UAL26 containing plasmids pCB101, pCB103 and pCB104 all produced a bacteriocin at a similar level that inhibited the growth of E.coli DH5a. C.
maltoromaticum UAL26 containing pCB104 showed resistance to brochocin-C, but sensitivity to chloramphenicol.

Example 10 Use of promoter P15 to express the production of colicin VM in a feed-grade vector To produce colicin VM using a feed-grade vector in strains of Lactobacilli that are unable to produce colicin V, recombinant PCR technique and subcioning were performed. The P15 promoter was amplified by PCR as before using primers MP11 forward and primer A (See Figure 11) and template pGKV210-P15. co1VM gene was amplified by PCR using primers B and C and template pCB23M. Recombinant PCR
was used to amplify a DNA fragment containing P15 promoter, the signal peptide of divergicin A, and the co1VM. The fragment was amplified using primers MP11 forward and C and the PCR products containing P15 promoter and colVM gene from above as templates.
The fragment obtained cut by EcoRl and dCpnl and inserted into plasmid pCB104 appropriate sites by replacing the EcoRllKpnl fragment in pCB104. The resulting plasmid pCB110 is feed-grade vector containing P15 promoter and signal peptide of divergicin A fused to coNM (Figure 15). Alternatively, a feed-grade plasmid, designated as pCB111, was constructed by replace the P32 promoter in pCB23M with P15 promoter. Plasmid pCB111 is similar to pCB23M except it has the P15 promoter instead of P32 promoter. C. maltatomaticum UAL26 containing pCB110 or pCB111 shows activity against E. coli, sensitivity to chloramphenicol, and resistance to brochocin C.
Plasmid pCB110 and pCB111 were transformed into L. reuteri CB4. Strain L.
reuteri CB4 containing pCB110 or pCB111 inhibited the growth of E. coli, was sensitive to chloramphenicol and resistant to brochocin C.

REFERENCES CITED.

Ahn, C., Collins-Thompson, D., Duncan, C., and Stiles, M.E. 1992. Mobilization and location of the genetic determinant of chloramphenicol resistance from Lactobacillus plantarum caTC2R. Plasmid 27: 16-176.

Franz, C.M.A.P., van Belkum, M.J., Worobo, R.W., Vederas, J.C., and Stiles, M.E.
2000. Characterization of the genetic locus responsible for production and immunity of carnobacteriocin A: the immunity gene confers cross-protection to enterocin B.
Microbiology 146: 621-631.

Jewell, B., and Collins-Thompson, D.L. 1989. Characterization of chloramphenicol resistance in Lactobacillus plantarum caTC2R. Curr. Microbiol. 19: 343-346.
McCormick, J.K., Poon, A., Sailer, M., Gao, Y., Roy, K.L., McMullen, L.M., Vederas, J.C., Stiles, M.E., and van Belkum, M.J. 1998. Genetic characterization and heterologous expression of brochocin-C, an antibotulinal, two-peptide bacteriocin produced by Brochothrix campestris ATCC43754. Appi. Environ. Microbiol. 64:

4766.

McCormick, J.K., Klaenhammer, T.R., and Stiles, M.E. 1999. Colicin V can be produced by lactic acid bacteria. Lett. Appi. Microbiol. 29: 37-41.

Sambrook, J., Fritsch, E.F., and Maniatis, T. 1989. Molecular Cloning: A
Laboratory Manual, 2"d edn. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press.
Sanger, F., Nicklen, S., Coulson, A.R. 1977. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. 74: 5463-5467.

Stiles, M.E., Vederas, J.C., van Belkum, M.J., Worobo, R.W., Worobo, R.J., McCormick, J.K., Greer, G.G., McMullen, L.M., Leisner, J.J., Poon, A., Franz, C.M.A.P.
2002. Bacteriocins, transport and vector system and method of use thereof. US
Pat.
6,403,082.

van Belkum, M.J., and Stiles, M.E. 1995. Molecular characterization of genes involved in the production of the bacteriocin leucocin A from Leuconostoc gelidum.
Appl.
Environ. Microbiol. 61: 3573-3579.

Van der Vossen, J.M.B.M., Kok, J., and Venema, G. 1985. Construction of cloning, promoter-screening, and terminator-screening shuttle vectors for Bacillus subtilis and Lactococcus lactis subsp. lactis. Appl. Environ. Microbiol. 50: 540-542.

van der Vossen, J.M.B.M., van der Lelie, D., and Venema, G. 1987. Isolation and characterization of Streptococcus cremoris Wg2-specific promoters. Appl.
Environ.
M icrobiol . 53: 2452-2457.

Wilson, K.H., Blitchington, R.B., and Greene, R.C. 1990. Amplification of bacterial 16S
ribosomal DNA with polymerase chain reaction. J. Clin. Microbiol. 28: 1942-1946.
Worobo, R.W., van Belkum, M.J., Sailer, M., Roy, K.L., Vederas, J.C., and Stiles, M.E.
1995. A signal peptide secretion-dependent bacteriocin from Carnobacterium divergens. J. Bacteriol. 177: 3143-3149.

Claims (40)

IN THE CLAIMS:
We claim:

1. An expression vector for the secretion of a polypeptide comprising a promoter, a signal sequence operatively associated with the polypeptide, a DNA sequence encoding a mutated colicin V, and a terminator.

2. The expression vector of claim 1 wherein the mutated colicin V comprises Sequence I.D. No. 1.

3. The on vector of claim 1 wherein the mutated colicin V comprises Sequence I.D.
No. 3.

4. The expression vector of claim 1 further comprising nucleotide sequences encoding an immunity gene.

5. The expression vector of claim 4 wherein the immunity gene is a bacteriocin immunity gene.

6. The expression vector of claim 5 wherein the bacteriocin immunity gene is one or more immunity genes selected from the group consisting of carnobacteriocin A
and brochocin-C.

7. The expression vector of claim 1 that encodes an amino acid sequence corresponding to Seq. I.D. No. 2.

8. The expression vector of claim 1 that encodes an amino acid sequence corresponding to Seq. I.D. No. 4.

9. The expression vector of claim 1 wherein the promoter is selected from the group consisting of P32 and P15.

10. The expression vector of claim 9 wherein the promoter comprises P15 nucleotide sequences.

11. The expression vector of claim 1 wherein the vector does not include a functional antibiotic resistance gene.

12. The expression vector of claim 1 wherein the signal peptide is divergicin A.

13. A method for producing colicin VM comprising introducing an expression vector in a suitable host, wherein said expression vector comprises nucleotide sequences encoding colicin VM, and wherein said host is a lactic acid bacterium; and secreting said colicin VM from the host.

14. A mutant colicin V bacteriocin comprising the protein encoded by nucleotide sequences corresponding to Sequence I.D. No. 1.

15. The mutant colicin V bacteriocin of claim 14 wherein the protein is encoded by nucleotide sequences corresponding to Sequence I.D. No. 3.

16. A composition comprising the expression vector of claim 1.

17. A lactic acid bacterium comprising the expression vector of claim 1.

18. A method of treating an E. coli diseases or conditions comprising administering an effective amount of a lactic acid bacterium host having an expression vector therein that secretes colicin VM; contacting said E. coli with said lactic acid bacterium; and allowing said colicin VM to act against said E. coli.

19. A method of inhibiting a Gram-negative bacterium comprising contacting a Gram-negative bacterium with a Gram-positive bacterium, wherein said Gram-positive bacterium secretes an anti-bacterial substance effective against said Gram-negative bacterium.

20. The method of claim 19 wherein the Gram-negative bacterium is E. coli.

21. The method of claim 19 wherein the Gram-positive bacterium is a lactic acid bacterium.

22. The method of claim 19 wherein the anti-bacterial substance is a peptide or protein.

23. The method of claim 22 wherein the protein is a bacteriocin.

24. The method of claim 23 wherein the bacteriocin is selected from the group consisting of colicin V, colicin VM, and combinations thereof.

25. An expression vector for the secretion of a polypeptide effective against a Gram-negative bacterium by a Gram-positive host comprising nucleotide sequences for at least one pre-selected polypeptide effective against a Gram-negative bacterium; a promoter operatively associated with said nucleotide sequences; a signal peptide operatively associated with said nucleotide sequences and effective in said Gram-positive host; a selection marker comprising nucleotide sequences corresponding to a bacteriocin immunity gene; and a suitable replicon.

26. A method of treating enterotoxigenic E. coli in pigs comprising administering an effective amount of lactic acid bacteria, said bacteria comprising an expression vector that produces colicin VM.

27. The method of claim 26 wherein said expression vector is a feed grade vector.

28. The method of claim 27 wherein the feed grade vector comprises a bacteriocin immunity gene.

29. The method of claim 24 wherein said expression vector comprises a signal peptide suitable for expressing a Gram-negative bacteriocin in a Gram-positive host.

30. The method of claim 27 wherein the signal peptide is col V.

31. The method of claim 27 further comprising a lactic acid bacterium that produces an anti-E. coli substance that is not colicin VM.

32. The method of claim 31 wherein the anti e-coli substance comprises colicin V.

33. The method of claim 33 wherein the expression vector is selected from the group consisting of pCB110, PCB111, pCB15s, pCB19, pCB22, and pCB23m.

34. The expression vector of claim 1 wherein the expression vector is selected from the group consisting of pCB110, PCB111, pCB15s, pCB19, pCB22, and pCB23m.

35. A composition comprising a bacterium that expresses colicin VM.

36. A composition comprising an expression vector that expresses colicin VM.

37. A composition comprising a bacteriocin comprising colicin VM.

38. A food or feed-grade expression vector for the secretion of a polypeptide effective against a Gram-negative bacterium by a Gram-positive host, comprising nucleotide sequences for at least one pre-selected polypeptide effective against a Gram-negative bacterium; a promoter operatively associated with said nucleotide sequences; a signal peptide operatively associated with said nucleotide sequences and effective in said Gram-positive host; a selection marker comprising nucleotide sequences corresponding to a bacteriocin immunity gene; and a suitable replicon;
wherein said expression vector lacks an antibiotic resistance gene.

39. The food or feed grade expression vector of claim 38 wherein said expression vector includes a polylinker having multiple restriction sites.

40. The food or feed grade expression vector of claim 38 wherein said expression vector is an expression vector selected from the group consisting of pCB23M, pCB110, and pCB111.